Rotator Cuff TearPhase 4NCT02850211
A Selective COX-2 Inhibitor Provides Pain Control But Hinders Healing Following Arthroscopic Rotator Cuff Repair
A Phase 4 study testing Celecoxib, Ibuprofen and Tramadol in people with Rotator Cuff Tear, run by Seoul National University Bundang Hospital.
Trial summary
Selective cyclooxygenase (COX)-2 inhibitors are commonly used analgesics that provide similar analgesia but reduced adverse effects compared to other analgesics. However, few studies have been conducted on postoperative pain and tendon-to-bone healing. Read more about this study
- Who is it for?
- Ages 35 to 80 yearsHealthy volunteers can take part
- Conditions the study is for
- Rotator Cuff Tear
- What is being tested?
- Celecoxib, Ibuprofen and Tramadol
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 180 participants
- Where
- No sites listed yet
- Study dates
- Sep 2011to Nov 2015
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 35 to 80 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Patients scheduled to undergo arthroscopic acromioplasty and rotator cuff repair for a partial or full thickness tear
- Age < 80 years at time of diagnosis
- Patient willing and able to comply with the study prescriptions
- Patient able to give written informed consent before patient registration/randomisation
Who cannot join
- Patients with rotator cuff tear arthropathy
- Severe osteoarthritis (Samilson-Prieto grade II or higher)
- Rheumatoid arthritis
- Chronic renal failure (i.e., at high risk for the use of NSAIDs or opioid drugs)
- Liver failure
- Myocardial infarction or chronic heart failure
Show all 12Show fewer
- Cerebral vascular disease
- Active gastric ulcer or bleeding
- Allergies to NSAIDs or opioid drugs
- Previous surgery on the same side
- Pregnant or breast feeding patients
- Those not willing to participate in the trial
About this study
Official title: A Selective COX-2 Inhibitor Provides Pain Control But Hinders Healing Following Arthroscopic Rotator Cuff Repair: A Prospective Randomized Comparison
Selective cyclooxygenase (COX)-2 inhibitors are commonly used analgesics that provide similar analgesia but reduced adverse effects compared to other analgesics. However, few studies have been conducted on postoperative pain and tendon-to-bone healing. Here, the investigators investigated the effect of a selective COX-2 inhibitor on analgesia and tendon-to-bone healing following arthroscopic rotator cuff repair.
Read the detailed description
Participants Selection After obtaining institutional review board approval and written informed consent from all participants, the investigators prospectively enrolled 180 participants scheduled to undergo arthroscopic acromioplasty and rotator cuff repair for a partial or full thickness tear between September 2011 and August 2012.
A priori statistical power analysis was performed to calculate the number of subjects required. A difference of one point in the visual analogue scale (VAS) was defined as the minimal clinically important difference. With a power of 80% and an alpha of 0.05, the power analysis demonstrated that a sample size of 51 participants per group was needed. Assuming a dropout rate of 20%, the investigators calculated a sample size of 60 participants per group.
Participants were randomly assigned in equal numbers to receive selective COX-2 inhibitors (celecoxib; Celebrex® 200 mg bid, Pfizer, Korea), traditional NSAIDs (ibuprofen; Carol-F® 385 mg tid, Ildong, Korea), or opioid drugs (tramadol; Tridol® 50 mg bid, Yuhan, Korea) for 2 weeks from the first day after surgery.
Analgesic medication was not prescribed preoperatively. Subacromial participant-controlled analgesia (Automed 3200, Ace Medical, Seoul, Korea) was used for the first 48 hours postoperatively in all participants. Intravenous cefazolin was used as the postoperative antibiotic for one day. If participants could not tolerate pain with regular postoperative medication, oxycodone (IR codon 5 mg, Unimed, Korea) was administered as rescue medication; the maximum dosage was limited to 20 mg per day according to the investigators institution's standard postoperative pain control procedures for 2 weeks after surgery.
Clinical and Radiological Assessment Participants rated pain and satisfaction with medication using a VAS of 0 (no pain/no satisfaction) to 10 (unbearable pain/extreme satisfaction) preoperatively and 3 days and 2 weeks postoperatively. Administration of rescue medication and side effects were also recorded. Side effects were categorized into five categories: nausea/vomiting, somnolence/dizziness, gastrointestinal complications (constipation, diarrhea, abdominal discomfort), pruritus, and bruising; respiratory difficulties, renal failure, heart failure, and seizure were also evaluated.
Of the 180 participants, 82 were followed for at least 24 months after surgery. Shoulder functional scores were obtained based on range of motion (ROM) data, pain VAS scores, Constant-Murley Shoulder scores, American Shoulder and Elbow Surgeons scores, and Korean Shoulder Scoring system scores. Radiological integrity of the repaired rotator cuff was assessed using magnetic resonance imaging (MRI) in 70 participants (25 in the celecoxib group, 23 in the ibuprofen group, and 22 in the tramadol group) and ultrasonography in the remaining 12 participants . Postoperative rotator cuff integrity assessed using MRI was categorized as type I to V according to the classification developed by Sugaya et al. as follows: type I, sufficient thickness compared with the normal cuff and homogenously low intensity; type II, sufficient thickness compared with the normal cuff and partial high intensity; type III, insufficient thickness (less than half the thickness of the normal cuff) but no discontinuity, suggesting a partial-thickness delaminated tear; type IV, presence of a minor discontinuity in 1-2 slices on both oblique coronal and sagittal images, suggesting a small full-thickness tear; type V, presence of a major discontinuity in more than two slices on both oblique coronal and sagittal images, suggesting a medium or large full-thickness tear. Postoperative incomplete healing or re-tear was defined as either Sugaya type IV or V.
MRI and ultrasonography data were analyzed by a musculoskeletal radiologist with 10 years of experience who was blinded to the study. The deltoid muscle, subacromial/subdeltoid bursa, long head of the biceps tendon, and entire rotator cuff were examined, with special emphasis on the integrity of the subscapularis tendon, supraspinatus tendon, infraspinatus tendon, and teres minor tendon. The tendons were scanned along their long and short axes. The radiologist defined a full-thickness tear as incomplete healing or a re-tear, such as a hypoechoic full-thickness cleft inside the tendon, detachment of the tendon from the bone, insertion with medial dislocation, and non-visualization of the tendon.
Surgical Procedure and Postoperative Care The senior investigator conducted all surgical procedures arthroscopically using three portals: anterior, lateral, and posterior. In participants with a stiff shoulder, manipulation was performed with capsular release. Synovectomy, biceps procedures, and debridement for partially torn rotator cuff tendons were performed for the glenohumeral joint. After glenohumeral procedures, subacromial decompression was performed to remove inflamed bursal tissue, and acromioplasty was conducted with a motorized burr in almost all participants except those with an extremely thin acromion to yield a flat acromion undersurface and to ensure adequate working space for the repair. Distal clavicle resection was performed in selected participants. The anteroposterior and retraction size of the tear were measured with a calibrated probe, and footprint preparation was performed with a ring curette, rasp, and shaver to expose the bleeding bony surface. After anchors were inserted according to the selected repair technique, the loaded sutures were passed through the tendon using a flexible suture passer (Expressew®, Depuy Mitek, Raynham, MA) or a suture passer (Spectrum®, Linvatec, Largo, FL). All sutures were secured using the SMC knot. After subacromial procedures, the operator always returned to the glenohumeral joint for irrigation and to identify medial anchor pull-out, missed foreign materials, or biceps incorporated into rotator cuff repair.
All participants followed the same rehabilitation protocol. They wore an abduction brace for 5 weeks and started passive ROM after brace removal. Participants who had limited motion preoperatively started tolerable controlled passive motion right after pain had subsided postoperatively. Shrugging of the shoulder and active motion of the elbow (flexion, extension), forearm (supination, pronation), wrist, and hand were encouraged immediately after surgery. After brace weaning, active assisted ROM was performed according to a pre-established protocol for 6 weeks. After full passive ROM was obtained, muscle-strengthening exercises were started; all sports activities were permitted 6 months after surgery. All physical therapy protocols were followed with the cooperation and supervision of a rehabilitation physician.
Statistical Analysis Statistical analysis was performed using SPSS software (version 18.0E; SPSS Inc., Chicago, IL). Frequency and descriptive statistics were analyzed to determine the baseline characteristics, and the t-test, chi-square test, analysis of variance, and Mann-Whitney test were performed to compare the three groups. Tukey's post-hoc test and Bonferroni's test were used to determine the groups between which differences occurred. Statistical significance was set at P < 0.05.
- Conditions
- Rotator Cuff Tear
- Medical subject headings
- Rotator Cuff Injuries
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
CelecoxibDrug
Also called Celebrex
1 capsule of 200mg Celebrex PO(per oral) twice a day for 14 days
IbuprofenDrug
Also called Carol-F
1 tablet of 385mg Ibuprofen PO(per oral) twice a day for 14 days
TramadolDrug
Also called Tridol
1 tablet of 50mg Tramadol PO(per oral) twice a day for 14 days
| Study group | Role | What they receive |
|---|---|---|
| Celecoxib | Experimental | 1 capsule of 200mg Celebrex twice a day for 14 days Receives: Drug: Celecoxib |
| Traditional NSAIDs | Active comparator | 1 tablet of 385mg Ibuprofen twice a day for 14 days Receives: Drug: Ibuprofen |
| Opioid drug | Active comparator | 1 tablet of 50mg Tramadol twice a day for 14 days Receives: Drug: Tramadol |
What is being measured
The primary outcome is the main question the study is designed to answer.
Rotator cuff healing failure
Assessed by a musculoskeletal radiologist using MRI and ultrasonography
Measured: Day 730
Secondary outcomes (6)
Pain VAS score
Decrease in the VAS (pain in mm) from Day 0 to Day 730
Measured: Day 0, Day 3, Day 14 Day 730
Medication satisfaction VAS score
Increase in the VAS (satisfaction in mm) from Day 0 to Day 14
Measured: Day 0, Day 3 and Day 14
Adverse effects
frequency of adverse effects at Day 3 and Day 14
Measured: Day 3 and Day 14
Constant-Murley Shoulder score
Measured: Day 730
American Shoulder and Elbow Surgeons score
Measured: Day 730
Korean Shoulder Scoring System
Measured: Day 730
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Jul 2016 (estimated)
- Study startSep 2011
- Primary completionNov 2015
- Study completionNov 2015
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Rotator Cuff TearStudies of the same condition, open and under way.
- More trials run by Seoul National University Bundang HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 180 participants (actual)
Sponsor and investigators
- Lead sponsor
- Seoul National University Bundang Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Joo Han Oh, Seoul National University Bundang Hospital
- Investigators
- Joo Han Oh, MD, PhD, Study chair, Seoul National University Bundang Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02850211
- Sponsor's protocol ID
- B-1105/128-003
- Status last verified
- Jul 2016
- First submitted
- 21 Jul 2016
- Last updated
- 29 Jul 2016
- Results posted
- No
- Data monitoring committee
- Yes
- Individual data sharing
- Undecided
Publications
Oh JH, Seo HJ, Lee YH, Choi HY, Joung HY, Kim SH. Do Selective COX-2 Inhibitors Affect Pain Control and Healing After Arthroscopic Rotator Cuff Repair? A Preliminary Study. Am J Sports Med. 2018 Mar;46(3):679-686. doi: 10.1177/0363546517744219. Epub 2017 Dec 18.
PubMed 29253346
Study at a glance
From the registry record, last updated by the sponsor on 29 Jul 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Selective COX-2 Inhibitor Provides Pain Control But Hinders Healing Following Arthroscopic Rotator Cuff Repair: A Prospective Randomized Comparison
- ClinicalTrials.gov ID
- NCT02850211
- Acronym / sponsor ID
- B-1105/128-003
- Conditions
- Rotator Cuff Tear
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 180 participants (actual)
- Lead sponsor
- Seoul National University Bundang HospitalUniversity, hospital or other
- Study start
- Sep 2011
- Primary completion
- Nov 2015 (actual)
- Study completion
- Nov 2015 (actual)
- First posted
- 29 Jul 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Selective cyclooxygenase (COX)-2 inhibitors are commonly used analgesics that provide similar analgesia but reduced adverse effects compared to other analgesics. However, few studies have been conducted on postoperative pain and tendon-to-bone healing. Here, the investigators investigated the effect of a selective COX-2 inhibitor on analgesia and tendon-to-bone healing following arthroscopic rotator cuff repair.
Detailed description
Participants Selection After obtaining institutional review board approval and written informed consent from all participants, the investigators prospectively enrolled 180 participants scheduled to undergo arthroscopic acromioplasty and rotator cuff repair for a partial or full thickness tear between September 2011 and August 2012.
A priori statistical power analysis was performed to calculate the number of subjects required. A difference of one point in the visual analogue scale (VAS) was defined as the minimal clinically important difference. With a power of 80% and an alpha of 0.05, the power analysis demonstrated that a sample size of 51 participants per group was needed. Assuming a dropout rate of 20%, the investigators calculated a sample size of 60 participants per group.
Participants were randomly assigned in equal numbers to receive selective COX-2 inhibitors (celecoxib; Celebrex® 200 mg bid, Pfizer, Korea), traditional NSAIDs (ibuprofen; Carol-F® 385 mg tid, Ildong, Korea), or opioid drugs (tramadol; Tridol® 50 mg bid, Yuhan, Korea) for 2 weeks from the first day after surgery.
Analgesic medication was not prescribed preoperatively. Subacromial participant-controlled analgesia (Automed 3200, Ace Medical, Seoul, Korea) was used for the first 48 hours postoperatively in all participants. Intravenous cefazolin was used as the postoperative antibiotic for one day. If participants could not tolerate pain with regular postoperative medication, oxycodone (IR codon 5 mg, Unimed, Korea) was administered as rescue medication; the maximum dosage was limited to 20 mg per day according to the investigators institution's standard postoperative pain control procedures for 2 weeks after surgery.
Clinical and Radiological Assessment Participants rated pain and satisfaction with medication using a VAS of 0 (no pain/no satisfaction) to 10 (unbearable pain/extreme satisfaction) preoperatively and 3 days and 2 weeks postoperatively. Administration of rescue medication and side effects were also recorded. Side effects were categorized into five categories: nausea/vomiting, somnolence/dizziness, gastrointestinal complications (constipation, diarrhea, abdominal discomfort), pruritus, and bruising; respiratory difficulties, renal failure, heart failure, and seizure were also evaluated.
Of the 180 participants, 82 were followed for at least 24 months after surgery. Shoulder functional scores were obtained based on range of motion (ROM) data, pain VAS scores, Constant-Murley Shoulder scores, American Shoulder and Elbow Surgeons scores, and Korean Shoulder Scoring system scores. Radiological integrity of the repaired rotator cuff was assessed using magnetic resonance imaging (MRI) in 70 participants (25 in the celecoxib group, 23 in the ibuprofen group, and 22 in the tramadol group) and ultrasonography in the remaining 12 participants . Postoperative rotator cuff integrity assessed using MRI was categorized as type I to V according to the classification developed by Sugaya et al. as follows: type I, sufficient thickness compared with the normal cuff and homogenously low intensity; type II, sufficient thickness compared with the normal cuff and partial high intensity; type III, insufficient thickness (less than half the thickness of the normal cuff) but no discontinuity, suggesting a partial-thickness delaminated tear; type IV, presence of a minor discontinuity in 1-2 slices on both oblique coronal and sagittal images, suggesting a small full-thickness tear; type V, presence of a major discontinuity in more than two slices on both oblique coronal and sagittal images, suggesting a medium or large full-thickness tear. Postoperative incomplete healing or re-tear was defined as either Sugaya type IV or V.
MRI and ultrasonography data were analyzed by a musculoskeletal radiologist with 10 years of experience who was blinded to the study. The deltoid muscle, subacromial/subdeltoid bursa, long head of the biceps tendon, and entire rotator cuff were examined, with special emphasis on the integrity of the subscapularis tendon, supraspinatus tendon, infraspinatus tendon, and teres minor tendon. The tendons were scanned along their long and short axes. The radiologist defined a full-thickness tear as incomplete healing or a re-tear, such as a hypoechoic full-thickness cleft inside the tendon, detachment of the tendon from the bone, insertion with medial dislocation, and non-visualization of the tendon.
Surgical Procedure and Postoperative Care The senior investigator conducted all surgical procedures arthroscopically using three portals: anterior, lateral, and posterior. In participants with a stiff shoulder, manipulation was performed with capsular release. Synovectomy, biceps procedures, and debridement for partially torn rotator cuff tendons were performed for the glenohumeral joint. After glenohumeral procedures, subacromial decompression was performed to remove inflamed bursal tissue, and acromioplasty was conducted with a motorized burr in almost all participants except those with an extremely thin acromion to yield a flat acromion undersurface and to ensure adequate working space for the repair. Distal clavicle resection was performed in selected participants. The anteroposterior and retraction size of the tear were measured with a calibrated probe, and footprint preparation was performed with a ring curette, rasp, and shaver to expose the bleeding bony surface. After anchors were inserted according to the selected repair technique, the loaded sutures were passed through the tendon using a flexible suture passer (Expressew®, Depuy Mitek, Raynham, MA) or a suture passer (Spectrum®, Linvatec, Largo, FL). All sutures were secured using the SMC knot. After subacromial procedures, the operator always returned to the glenohumeral joint for irrigation and to identify medial anchor pull-out, missed foreign materials, or biceps incorporated into rotator cuff repair.
All participants followed the same rehabilitation protocol. They wore an abduction brace for 5 weeks and started passive ROM after brace removal. Participants who had limited motion preoperatively started tolerable controlled passive motion right after pain had subsided postoperatively. Shrugging of the shoulder and active motion of the elbow (flexion, extension), forearm (supination, pronation), wrist, and hand were encouraged immediately after surgery. After brace weaning, active assisted ROM was performed according to a pre-established protocol for 6 weeks. After full passive ROM was obtained, muscle-strengthening exercises were started; all sports activities were permitted 6 months after surgery. All physical therapy protocols were followed with the cooperation and supervision of a rehabilitation physician.
Statistical Analysis Statistical analysis was performed using SPSS software (version 18.0E; SPSS Inc., Chicago, IL). Frequency and descriptive statistics were analyzed to determine the baseline characteristics, and the t-test, chi-square test, analysis of variance, and Mann-Whitney test were performed to compare the three groups. Tukey's post-hoc test and Bonferroni's test were used to determine the groups between which differences occurred. Statistical significance was set at P < 0.05.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Celecoxib | Experimental | Drug: Celecoxib1 capsule of 200mg Celebrex twice a day for 14 days |
| Traditional NSAIDs | Active comparator | Drug: Ibuprofen1 tablet of 385mg Ibuprofen twice a day for 14 days |
| Opioid drug | Active comparator | Drug: Tramadol1 tablet of 50mg Tramadol twice a day for 14 days |
Who may qualify
- Ages
- 35 to 80 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Patients scheduled to undergo arthroscopic acromioplasty and rotator cuff repair for a partial or full thickness tear
- Age < 80 years at time of diagnosis
- Patient willing and able to comply with the study prescriptions
- Patient able to give written informed consent before patient registration/randomisation
Key exclusion criteria (12 listed)
- Patients with rotator cuff tear arthropathy
- Severe osteoarthritis (Samilson-Prieto grade II or higher)
- Rheumatoid arthritis
- Chronic renal failure (i.e., at high risk for the use of NSAIDs or opioid drugs)
- Liver failure
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| CelecoxibAlso: Celebrex1 capsule of 200mg Celebrex PO(per oral) twice a day for 14 days | Drug | Celecoxib |
| IbuprofenAlso: Carol-F1 tablet of 385mg Ibuprofen PO(per oral) twice a day for 14 days | Drug | Traditional NSAIDs |
| TramadolAlso: Tridol1 tablet of 50mg Tramadol PO(per oral) twice a day for 14 days | Drug | Opioid drug |
Primary outcome
Rotator cuff healing failure
Time frame: Day 730
Assessed by a musculoskeletal radiologist using MRI and ultrasonography
6 secondary outcomes
Pain VAS score
Time frame: Day 0, Day 3, Day 14 Day 730
Medication satisfaction VAS score
Time frame: Day 0, Day 3 and Day 14
Adverse effects
Time frame: Day 3 and Day 14
Constant-Murley Shoulder score
Time frame: Day 730
American Shoulder and Elbow Surgeons score
Time frame: Day 730
Korean Shoulder Scoring System
Time frame: Day 730
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Jul 2016.
- Derived from this study: PubMed 29253346Oh JH, Seo HJ, Lee YH, Choi HY, Joung HY, Kim SH. Do Selective COX-2 Inhibitors Affect Pain Control and Healing After Arthroscopic Rotator Cuff Repair? A Preliminary Study. Am J Sports Med. 2018 Mar;46(3):679-686. doi: 10.1177/0363546517744219. Epub 2017 Dec 18.
- Individual participant dataSharing planned: Undecided
Related trials for Rotator Cuff Tear
Not yet recruiting
Voll Non-Degradable Shoulder Spacer FIH Study
Massive Rotator Cuff Tears, Massive Rotator Cuff Tear
Active, not recruiting
BioBrace® Implant for Arthroscopic Repair of Full Thickness Rotator Cuff Tears
Rotator Cuff Tears
Active, not recruiting
Lyophilized Platelet-Rich Plasma Lysate vs Dextrose Prolotherapy for Partial Rotator Cuff Tears
Rotator Cuff Tear, Rotator Cuff Syndrome
Active, not recruiting
Efficacy and Safety of Digital Therapeutics for Improving Shoulder Function After Rotator Cuff Repair
Rotator Cuff Tear Arthropathy, Repair of a Cuff Tear
Recruiting
Arthroscopic Rotator Cuff Repair With Long Head of Biceps Transposition and Acellular Dermal Matrix Augmentation for Large to Massive Incompletely Repairable Rotator Cuff Tears
Rotator Cuff Tears, Rotator Cuff Injuries
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Joo Han Oh, MD, PhD study chair
Seoul National University Bundang Hospital
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Celecoxib, Ibuprofen and Tramadol in people with Rotator Cuff Tear, run by Seoul National University Bundang Hospital.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 29 Jul 2016. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Rotator cuff healing failure (time frame: Day 730). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02850211, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Jul 2016; AzTrials last refreshed its copy on 6 Nov 2026.